Document:

<PAGE>

                                                             Exhibit 10(pp)

                                LICENSE AGREEMENT

            THIS LICENSE AGREEMENT is executed as of the 19th day of May, 2000
(the "Effective Date"), by and between ALLIANCE PHARMACEUTICAL CORP., a New York
corporation (hereinafter referred to as "Alliance") having its principal office
at 6175 Lusk Boulevard, San Diego, California 92121 and PFC THERAPEUTICS, LLC, a
Delaware corporation having its principal office at Baxter Healthcare
Corporation, Route 120 & Wilson Road, Round Lake, Illinois 60073 (hereinafter
referred to as "Licensee").

                              W I T N E S S E T H:

            WHEREAS, Alliance is developing through its research activities
certain products having medical applications, and owns and has the right to
grant rights and licenses under the Licensed Patents (hereinafter defined) and
the Know-How (hereinafter defined);

            WHEREAS, Licensee has, based on its evaluation, expressed to
Alliance its interest in obtaining from Alliance certain rights and licenses to
use, manufacture, formulate, market, sell and distribute certain products in the
Territory (hereinafter defined); and

            WHEREAS, Alliance is willing to grant such rights and licenses to
Licensee under the terms and conditions hereinafter set forth.

            NOW, THEREFORE, in consideration of the mutual promises, covenants
and agreements hereinafter set forth, both parties to this Agreement mutually
agree as follows:

1. DEFINITIONS. The following terms, when capitalized in this Agreement shall,
unless the context clearly indicates to the contrary, have the meanings set
forth in this Article:

      1.1 "Additional Products" shall mean injectable pharmaceutical products,
not included in Licensed Product, which augment oxygen delivery in surgical and
other patients at risk of acute tissue hypoxia.

      1.2 "Additional Territory" shall mean a country in the world for which
Licensee exercises its rights under Section 2.6 of this Agreement and which
shall be added to Schedule A attached hereto.

      1.3 "Affiliate" shall mean any entity controlling, controlled by, or under
common control with a person or other entity. For purposes of this definition,
the terms "controlling," "controlled by" or "under common control with" shall
mean the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a person or entity or through the
ownership of at least 40% of the voting securities of a person or entity.

      1.4 "Agreement" shall mean this License Agreement.

      1.5 "Baxter" shall mean Baxter Healthcare Corporation and its Affiliates.

      1.6 "Baxter Marketing Agreement" shall mean the marketing and distribution

* Indicates confidential information which has been omitted and filed separately
with The Securities and Exchange Commission.

<PAGE>

agreement between Baxter and Licensee dated May 19, 2000.

      1.7 "FDA" shall mean the United States Food & Drug Administration and,
when appropriate, hereinafter shall also mean any corresponding regulatory
agency in any country.

      1.8. "First Indication" shall mean Regulatory Approval of the Licensed
Product's use in a surgical setting to enhance systemic oxygenation and/or to
reduce patients' exposure to allogeneic blood transfusions.

      1.9. "Initial Territory" shall mean the countries listed on Schedule A
attached hereto .

      1.10 "Insolvency" shall mean a financial condition of a party such that
the sum of such party's debts is greater than the value of all of such party's
property, at a fair market valuation, exclusive of: (i) property transferred,
concealed or removed with intent to hinder, delay or defraud such entity's
creditors; and (ii) property that may be exempted from property of such party's
estate.

      1.11 "Know-How" shall mean designs, plans, specifications, methods,
systems, clinical data, processes, compositions, techniques and other technical
information or documentation, whether patentable or not, that is solely owned by
Alliance, or which Alliance has the right to control the use of through a
license or otherwise, relating to the Licensed Product.

      1.12 "Licensed Patent" shall mean:

            a) any patent listed in Schedule B ("Patent") or added thereto
during the term of this Agreement;

            b) any patent application listed in Schedule C ("Patent
Application") or added thereto during the term of this Agreement, and any
division, continuation, or continuation-in-part of any such application; and any
patent which shall issue based on such application, division, continuation or
continuation-in-part;

            c) any patent which is a reissue or extension of or a patent of
addition to, any patent defined in (a) or (b) above;

            d) any patent application or patent corresponding to any patent
application or patent identified in (a), (b), or (c), above which is filed or
issued in any country; and

            e) any patent or patent application related to or based on any
Know-How related to Licensed Product or the manufacture thereof developed,
licensed or acquired by Alliance prior to or during the term of this Agreement
and which is necessary for the manufacture, use or sale of any Licensed Product
and any division, continuation or continuation-in-part of any such patent or
patent application; and any patent which shall issue based on such application,
division, continuation or continuation-in-part; and any patent which is a
reissue or extension of, or a patent of addition to, any such patent.

            It shall be understood that the term "Licensed Patent" shall also
include any Supplementary Certificate of Protection of a Member State of the
European Community and

                                       2
<PAGE>

other similar protective rights in any other country of the Territory.

      1.13 "Licensed Product" shall mean all injectable perfluorochemical
emulsions capable of transporting oxygen in therapeutic effective amounts in the
bloodstream for all medical uses, including therapeutic and diagnostic, that
Alliance has evaluated, developed or acquired prior to the date of this
Agreement, or that will be evaluated, developed or acquired under this
Agreement, to the extent that such emulsions are owned or controlled by
Alliance.

      1.14 "NDA" shall mean a New Drug Application and all supplements filed
pursuant to the requirements of the FDA, including all documents, data and other
information concerning Licensed Product which are necessary for, or included in,
FDA approval to market Licensed Product as more fully defined in 21 C.F.R.
ss.ss.314.5 et seq. as well as equivalent submissions to the appropriate health
authorities in other countries in the Territory, provided further that with
respect to the European Union, such application is to be under the E. U.
Centralized Procedure.

      1.15 "Net Sales" shall mean the gross sales of Licensed Product in
finished packaged form sold by Licensee, less returns or replacements actually
granted, less excise, value added and other taxes applicable to sales of
Licensed Product which Licensee has to pay or absorb on such sales in the
Territory.

      1.16 "Operating Agreement" shall mean the Licensee Limited Liability
Operating Agreement dated May 17, 2000 between Alliance and Baxter.

      1.17 "Regulatory Approval" means (1) in the United States, approval from
the FDA for marketing and promotion of the Licensed Product, or (2) outside of
the United States, an analogous order by a non-U.S. governmental agency which
requires regulatory approval prior to marketing and promotion of the Licensed
Product in such non-U.S. country.

      1.18 "Territory" shall mean the Initial Territory and any Additional
Territory, as listed on Schedule A as the same may be amended from time to time.

      1.19 "Third Party" shall mean any person, corporation or unincorporated
body other than Licensee and Alliance and their Affiliates.

2. LICENSE GRANT

      2.1 Marketing License. Alliance grants to Licensee on an exclusive basis
the rights and licenses under the Licensed Patents and Know-How to use, market,
sell and distribute Licensed Product in the Territory. Licensee will use
reasonable efforts to commercialize the Licensed Product throughout the
Territory.

      2.2 Manufacturing License. Alliance grants to Licensee an exclusive right
to manufacture Licensed Product anywhere in the world for sale and distribution
in the Territory.

      2.3 License Restriction. Alliance agrees not to license Licensed Patents
and/or Know-How, without the prior written consent of Licensee which shall not
be unreasonably withheld, to any Third Party to manufacture, use, market, sell
or distribute any product which is capable of transporting oxygen in therapeutic
effective amounts in the bloodstream for any

                                       3
<PAGE>

medical use in the Territory that falls within the scope of a valid claim of a
Licensed Patent.

      2.4 Licensee Sublicenses. The rights and licenses granted hereunder to
Licensee shall be sublicensable by Licensee to its Affiliates or to a Third
Party. Notwithstanding the granting of a sublicense to a Third Party or an
Affiliate or a direct license to an Affiliate, Licensee shall remain responsible
to Alliance for all obligations of Licensee, its Affiliates and any sublicensee
Third Party.

      2.5 Distributors. Nothing herein shall preclude Licensee and/or its
Affiliates from utilizing a distributor to promote and distribute the Licensed
Product in any country of the Territory.

      2.6 Right of First Offer--Additional Territory. During the term of this
Agreement, before entering into any development, marketing or license agreement
for the Licensed Product in one or more countries outside the Territory with a
Third Party, Alliance will give Licensee notice (the "Alliance Territory
Notice"), with a copy to Baxter, containing its offer to Licensee to enter into
a development, marketing or license agreement for the Licensed Product in such
countries (the "Additional Territory"). The Alliance Territory Notice will
include the financial and other material terms which Alliance is prepared to
accept and, if requested by Licensee, Alliance will also make available its
clinical or other data reasonably necessary to permit Licensee to evaluate the
technical and marketing potential of the Licensed Product in such countries. In
addition, from time to time, Licensee may give Alliance notice (the "Licensee
Territory Notice"), with a copy to Baxter, containing its offer to enter into a
development, marketing or license agreement for the Licensed Product in one or
more countries outside the Territory. The Licensee Territory Notice will include
the financial and other material terms which Licensee is prepared to accept and,
if requested by Licensee, Alliance will make available its clinical or other
data reasonably necessary to permit Licensee to evaluate the technical and
marketing potential of the Licensed Product in such countries. For purposes of
this Section 2.6, "Territory Notice" shall refer to either an Alliance Territory
Notice or a Licensee Territory Notice.

      If requested by the party receiving the Territory Notice before the
expiration of a 60-day period (the "Initial Period") after receipt of the
Territory Notice, Alliance and Licensee will negotiate in good faith in order to
reach an agreement (a "Definitive Agreement") with respect to the terms set
forth in the Territory Notice; provided, however, that, if not so requested, or
if a Definitive Agreement shall not be executed before the expiration of a
120-day period (the "Second Period") following receipt of an Alliance Territory
Notice, Alliance may negotiate and execute a Definitive Agreement with one or
more Third Parties on terms no more favorable to the Third Party than the last
terms offered by Alliance to Licensee. During the Initial Period and, if
applicable, during the Second Period, Alliance will not enter into a Definitive
Agreement with any Third Party, provided that, if at the time Alliance receives
Licensee Territory Notice, it is in negotiations with a Third Party, Alliance
may continue such negotiations and enter into a Definitive Agreement with such
Third Party. In the event of any dispute as to the value of the financial and
other material terms included in the Territory Notice, any party may refer such
dispute to a mutually acceptable Third Party, whose decision shall be final,
conclusive and binding upon the parties hereto and whose fees and expenses shall
be borne one-half by Licensee and one-half by Alliance. In the event that the
parties cannot agree on a mutually acceptable

                                       4
<PAGE>

Third Party, then the dispute will be submitted to arbitration pursuant to
Section 11.3 herein. In the case of an Alliance Territory Notice, in the event
the Initial Period expires or, if applicable, the Second Period expires without
a Definitive Agreement, and Alliance does not enter into an agreement with a
Third Party, Alliance shall repeat the process set forth in this Section 2.6.

      2.7 Right of First Offer--Additional Product. During the term of this
Agreement, before entering into any development, marketing or license agreement
for an Additional Product in the Territory with a Third Party, Alliance will
give Licensee notice (the "Alliance Product Notice"), with a copy to Baxter,
containing its offer to Licensee to enter into a development, marketing or
license agreement for the Additional Product. The Alliance Product Notice will
include the financial and other material terms which Alliance is prepared to
accept and, if requested by Licensee, Alliance will also make available its
clinical or other data reasonably necessary to permit Licensee to evaluate the
technical and marketing potential of the Additional Product in such countries.
In addition, from time to time, Licensee may give Alliance notice (the "Licensee
Product Notice"), with a copy to Baxter, containing its offer to enter into a
development, marketing or license agreement for the Additional Product in the
Territory. The Licensee Product Notice will include the financial and other
material terms which Licensee is prepared to accept and, if requested by
Licensee, Alliance will make available its clinical or other data reasonably
necessary to permit Licensee to evaluate the technical and marketing potential
of the Additional Product in such countries. For purposes of this Section 2.7,
"Product Notice" shall refer to either an Alliance Product Notice or a Licensee
Product Notice.

      If requested by the party receiving the Product Notice before the
expiration of a 60-day period (the "First Period") after receipt of the Product
Notice, Alliance and Licensee will negotiate in good faith in order to reach an
agreement (a "Definitive Agreement") with respect to the terms set forth in the
Product Notice; provided, however, that, if not so requested, or if a Definitive
Agreement shall not be executed before the expiration of a 120-day period (the
"Negotiation Period") following receipt of an Alliance Product Notice, Alliance
may negotiate and execute a Definitive Agreement with one or more Third Parties
on terms no more favorable to the Third Party than the last terms offered by
Alliance to Licensee. During the First Period and, if applicable, during the
Negotiation Period, Alliance will not enter into a Definitive Agreement with any
Third Party, provided that, if at the time Alliance receives the Licensee
Product Notice, it is in negotiations with a Third Party, Alliance may continue
such negotiations and enter into a Definitive Agreement with such Third Party.
In the event of any dispute as to the value of the financial and other material
terms included in the Product Notice, any party may refer such dispute to a
mutually acceptable Third Party, whose decision shall be final, conclusive and
binding upon the parties hereto and whose fees and expenses shall be borne
one-half by Licensee and one-half by Alliance. In the event that the parties
cannot agree on a mutually acceptable Third Party, then the dispute will be
submitted to arbitration pursuant to Section 11.3 herein. In the case of an
Alliance Product Notice, in the event the First Period expires or, if
applicable, the Negotiation Period expires without a Definitive Agreement, and
Alliance does not enter into an agreement with a Third Party, Alliance shall
repeat the process set forth in this Section 2.7.

3. ROYALTIES

      3.1 Royalties. In consideration of the rights and licenses granted to
Licensee under

                                       5
<PAGE>

Article 2 of this Agreement, Licensee shall pay to Alliance * of Licensed
Products in the Territory. Additionally, within five (5) business days after
the execution of this Agreement, Licensee shall pay Alliance a prepaid
royalty of $10 million. Such amount shall be credited against the first $10
million of future royalty obligations.

      3.2 Markets. Licensee shall have the final decision with respect to all
aspects of commercialization or non-commercialization of Licensed Product in any
country in the Territory including but not limited to sales, marketing and
distribution.

      3.3 Royalty Calculation. The parties agree to negotiate in good faith for
an equitable determination of Net Sales of Licensed Product in the event that
Licensee sells Licensed Product in such a manner that the gross sales of same
are not readily identifiable.

4. REPORTS AND RECORDS

      4.1 Records. Licensee shall keep true and accurate records of sales of
Licensed Product and Net Sales and the royalties payable to Alliance under
Article 3 hereof and shall deliver to Alliance a written statement thereof on or
before the forty-five (45) day following the end of each Licensee accounting
quarter (or any part thereof in the first or last calendar quarter of this
Agreement) for such Licensee accounting quarter. Said written statements shall
set forth Licensee's Net Sales and the calculation thereof for each Licensed
Product and the royalties due thereon.

      4.2 Exchange Rate. All royalty payments by Licensee to Alliance shall be
converted into U.S. Dollars at the average rate of exchange for the calendar
quarter for which royalty payments are being remitted according to Licensee's
normal procedures for calculating same and shall be made by wire transfer to a
designated Alliance account prior to sixty (60) days following the end of each
Licensee accounting quarter. If the transfer or the conversion into U.S. Dollars
in any such instance is not lawful or possible, the payment of each part of the
royalties due as is necessary, shall be made by the deposit thereof, in whatever
currency is allowable, to the credit and account of Alliance in any commercial
bank or trust company of Alliance's choice located in that country. Prompt
notice of said deposit shall be given by Licensee to Alliance.

      4.3 Taxes. Any income or other taxes which Licensee is required to pay or
withhold on behalf of Alliance with respect to royalties and any other monies
payable to Alliance under this Agreement shall be deducted from the amount of
such royalties and monies due. Licensee shall furnish Alliance with proof of
such payments. Any such tax required to be paid or withheld shall be an expense
of and borne solely by Alliance.

      4.4 Audit. Alliance shall have the right to nominate an independent
certified public accountant reasonably acceptable to and approved by Licensee
who shall have access to Licensee and its Affiliates' records during reasonable
business hours for the purpose of verifying the royalties payable as provided in
this Agreement for the three (3) preceding years but this right may not be
exercised more than once in any calendar year, and once a calendar year is
audited it may not be reaudited, and said accountant shall disclose to Alliance
only information relating solely to the accuracy of the royalty report and the
royalty payments made according to this Agreement. Any underpayments due to
Alliance by Licensee shall be paid with interest at the

                                       6
<PAGE>

monthly rate which is the lesser of (i) one and one-half percent (1-1/2%) of the
amount due; and (ii) the maximum lawful interest rate permitted under applicable
law. Such interest shall accrue at such rate on a monthly basis on the balance
of unpaid amounts outstanding from the date on which portions of such amounts
become due and owing until payment thereof in full.

5. CONFIDENTIALITY

      5.1 Non-Disclosure. Alliance and Licensee realize that some information
received by one party from the other pursuant to this Agreement will be
confidential. It is therefore agreed that any information received by one party
from the other which is in writing, or reduced to writing within thirty (30)
days of the date of disclosure and designated as "Confidential," shall not
during or for a period of five (5) years after the term of this Agreement be (i)
disclosed by the receiving party to any third party, except to the extent that
(A) such third party is an employee, agent, representative or consultant for or
to Baxter, Alliance, Licensee or their Affiliates, or is contemplating investing
in Licensee or Alliance, (B) such third party has agreed in writing to abide to
these confidentiality obligations and (C) such third party has a need to know
such information in order for the parties to perform their obligations under
this Agreement, or (ii) used by the receiving party for purposes other than
those contemplated by this Agreement.

      5.2 Permitted Disclosure. Nothing in this Agreement shall prevent the
receiving party from disclosing any such information: (i) which is or becomes
publicly known through no fault of the receiving party; (ii) which the receiving
party rightfully had in its possession prior to the disclosure to the receiving
party, or is independently developed by the receiving party, in either case as
evidenced by written documentation; (iii) which the receiving party lawfully
obtained without restriction from a third party with no secrecy or
confidentiality obligation to the disclosing party; (iv) which is approved in
writing by the disclosing party for disclosure by the receiving party; or (v)
which is disclosed pursuant to court order or as otherwise compelled by law.

6. PATENTS

      6.1 Alliance Prosecution. Alliance agrees to faithfully continue, at its
sole expense, the prosecution of all Patent Applications listed in Schedule C
and, when necessary, to file and prosecute additional patent applications
covering patentable technology relating to the Licensed Product in at least the
countries set forth in Schedule D. Alliance shall have the duty and
responsibility to pay all taxes, maintenance fees and annuities on all Licensed
Patents listed in Schedules B and C. If so requested by Licensee, Alliance shall
provide Licensee with copies of all Patent Applications listed in Schedule C,
all future filed Patent Applications relating to the Licensed Product and all
correspondence with the Patent Offices in any countries of the Territory.

      6.2 Licensee Prosecution. If Alliance chooses not to prosecute and
maintain any Patent Applications and/or Patents under this Agreement, Alliance
shall promptly and timely so notify Licensee and Licensee shall, in its sole
discretion, decide whether to assume the responsibility and expenses therefor on
a country by country basis for each such Patent Application or Patent. In that
event, the Patent Applications and/or Patents for which Licensee shall assume
responsibility shall be assigned to Licensee.

                                       7
<PAGE>

      6.3 Patent Extension. The parties agree to cooperate in order to avoid
loss of any rights which may otherwise be available to the parties under the
U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the
Supplementary Certificate of Protection of the Member States of the European
Community and other similar measures in any other country in the Territory.
Without limiting the foregoing, any party receiving notice of an NDA approval to
market Licensed Products in the United States shall notify the other party and
shall, if applicable, timely supply such other party with all information
necessary to file an application for patent term extension within the sixty (60)
day period following NDA approval. The same shall apply with respect to the
approval by the health authorities in a country of the European Community or
approval by the appropriate authorities in any other country in the Territory.

7. REPRESENTATIONS AND WARRANTIES

      7.1 Authority to Enter into Agreement. Alliance represents and warrants
that it has full power and authority to enter into this Agreement and carry out
the transactions contemplated hereby, and that all necessary corporate action
has been duly taken in this regard.

      7.2 Ownership. Alliance represents and warrants that it is the sole and
exclusive owner of the entire right, title, and interest in and to the Licensed
Patents and the Know-How and that it has the right to grant the rights hereby
granted to Licensee. To the best of Alliance's information and belief as of the
Effective Date, practice of the Licensed Patents does not infringe on the
intellectual property rights of any third parties.

      7.3 Liens; Encumbrances. Alliance represents and warrants that it owns the
Know-How and Licensed Patents free and clear of any security interest, mortgage,
pledge, lien, encumbrance, claim, imperfection of title and any other right of
any third party of any kind or nature.

      7.4 Exclusive License. Alliance represents and warrants that no license or
other rights of any kind have been, or during the term of the license under this
Agreement will be, granted under or with respect to the Licensed Product in the
Territory, except as otherwise agreed to by the parties.

      7.5 Validity of Licensed Patents. Alliance represents and warrants that
Alliance has not engaged in any conduct, or omitted to perform any necessary
act, the result of which would invalidate the Licensed Patents or prevent their
enforceability, and Alliance is aware of no facts or claims that would cause the
Licensed Patents to be invalid or unenforceable.

      7.6 Absence of Litigation. Except as previously disclosed to Licensee in
writing, Alliance represents and warrants that there is no ongoing litigation,
arbitration, or other proceeding pending with respect to the Licensed Patents or
Know-How.

      7.7 Absence of Infringement. Alliance has not put a third party on notice
of actual or potential infringement of the Licensed Patents, Alliance has not
considered enforcement action(s) with respect to the Licensed Patents and is not
aware of any actual infringement of the Licensed Patents.

                                       8
<PAGE>

      7.8 Intellectual Property Rights of Third Parties. Alliance represents and
warrants that no person has made any claims or threatened, in writing or
otherwise, that the manufacture, use or sale of the Licensed Product violates,
would violate, infringes or would infringe any existing patent, trade name,
trademark, copyright, trade secret or other intellectual property right of such
person, nor has Alliance received any opinions of such infringement. To the best
of Alliance's knowledge, the manufacture, use or sale of the Licensed Product
does not infringe on the intellectual property rights of any Third Party.

      7.9 Maintenance Fees; Annuities. Alliance represents and warrants that all
maintenance fees, annuities, and the like have been paid when due and will be
timely paid by Alliance during the entire term of this Agreement.

      7.10 Absence of Consent. Alliance represents and warrants that no third
party consent, approval, or other authorization is or will be required to enter
into this Agreement.

      7.11 Absence of Royalties; Fees. Except as previously disclosed in
writing, Alliance represents and warrants that there are no royalties,
honoraria, fees or other payments payable by Alliance to any person by reason of
the ownership, use, license, sale or other disposition of the Licensed Patents.

8. INFRINGEMENT

      8.1 Licensee Infringement. If, as a result of the use or sale of the
Licensed Product in any country of the Territory or the manufacture thereof
anywhere in the world for distribution in the Territory, Licensee and/or its
Affiliate, distributor or sublicensee is sued for patent infringement or
threatened with such a lawsuit or other action by a Third Party, Licensee and
Alliance shall meet to analyze the infringement claim and avoidance of same. If
it is necessary to obtain a license from such Third Party, Licensee and Alliance
in negotiating such a license shall make every effort to minimize any license
fees and/or royalty payable to such Third Party. If the settlement of a lawsuit
or threatened lawsuit or other action requires any payments, including but not
limited to royalty payments, to a Third Party, then Licensee or its Affiliates
and Alliance shall share said payments on an equal basis.

      8.2 Third Party Infringement. In the event a party is informed that there
is infringement of a Licensed Patent on a commercial scale by a Third Party
involving the Licensed Product, such party or its Affiliates shall notify the
other party in writing to that effect, including with said written notice
evidence establishing a case of infringement by such Third Party. For a period
of one hundred and twenty (120) days from notice of the infringement, Alliance
shall have the first right, but not the obligation, in its reasonable
discretion, to bring suit against such Third Party infringer. Alliance shall
bear all the expenses of any suit brought by it and shall retain all damages or
other monies awarded or received in settlement of such suit. Licensee and/or its
Affiliates will cooperate with Alliance in any such suit and shall have the
right to consult with Alliance and be represented by its own counsel at its own
expense. If after the expiration of said one hundred and twenty (120) days from
the date of receipt of said notice, Alliance has not overcome the case of
infringement, obtained a discontinuance of such infringement, or brought suit
against the Third Party infringer, then Licensee shall have the right, in its
sole discretion, but not the obligation to bring such suit at its own expense
and in its own name, if possible. If

                                       9
<PAGE>

necessary, Alliance will permit the suit to be brought in its name. Licensee
shall bear all the expenses of any suit brought by it and shall retain all
damages or other monies awarded or received in settlement of such suit. Alliance
will cooperate with Licensee in any such suit and shall have the right to
consult with Licensee and be represented by its own counsel at its own expense.

9. TRADEMARKS. All trademarks to be utilized by Licensee and/or its Affiliates
on Licensed Products under this Agreement shall be chosen by Licensee and/or its
Affiliates and any new trademarks shall be owned by Licensee and/or its
Affiliates. Alliance and its Affiliates have no right to use Licensee's
trademarks on Licensed Products unless explicitly granted such right by Licensee
or unless this Agreement is terminated in accordance with Article 10 below. Upon
Licensee's request at any time, Alliance will grant an exclusive royalty-free
license for the use of Alliance's trademark(s), including the "Oxygent" and
"Augmented-ANH" trademarks throughout the Territory.

10. DURATION AND TERMINATION

      10.1 Duration. This Agreement shall become effective on the Effective Date
and shall, unless sooner terminated pursuant to any other provision of this
Agreement, continue in full force for the longer of (i) the last to expire of
the Licensed Patents or (ii) thirteen (13) years from the date of this
Agreement. Upon natural expiration of the term of this Agreement, pursuant to
Section 10.1, Licensee and/or its Affiliates shall have a fully paid-up,
irrevocable exclusive license to make and have made Licensed Product and to use,
market, sell and distribute Licensed Product in the Territory.

      10.2 Termination by Licensee. Notwithstanding any other provision herein,
Licensee can, prior to NDA approval for the First Indication, terminate this
Agreement in its entirety or on a country by country basis upon three (3) months
written notice to Alliance. After NDA approval of the First Indication for the
Licensed Product in any country in the Territory and prior to first commercial
sale of Licensed Product, Licensee may terminate this Agreement in the United
States and/or European Union on a country-by-country basis upon six (6) months
written notice to Alliance and in all other countries, on a country-by-country
basis, upon three (3) months written notice to Alliance. After the first
commercial sale of a Licensed Product, Licensee can terminate this Agreement in
the United States and/or the European Union on a country-by-country basis upon
nine (9) months written notice to Alliance and in all other countries on a
country-by-country basis upon three (3) months written notice to Alliance.

      10.3 Termination For Cause.

            a) Failure by Licensee or Alliance to comply with any of the
respective material obligations and conditions contained in this Agreement shall
entitle the other party to give the party in default notice requiring it to make
good such default. If such default, other than a monetary payment default, is
not cured within ninety (90) days after receipt of such notice, the notifying
party shall be entitled (without prejudice to any of its other rights conferred
on it by this Agreement) to terminate this Agreement by giving a notice to take
effect immediately. The time period for curing a monetary payment default shall
be thirty (30) days. The right of either party to terminate this Agreement as
hereinabove provided shall not be affected in any way by its

                                       10
<PAGE>

waiver of, or failure to take action with respect to any previous default.

            b) In the event of the Insolvency of one of the parties hereto, the
other party shall be entitled to terminate this Agreement forthwith by giving a
written notice to the first party.

      10.4 Rights and Obligations Upon Termination. In the event that this
Agreement is terminated in its entirety by Licensee in accordance with Section
10.2 or is terminated by Alliance pursuant to Section 10.3, Licensee undertakes:

            a) to deliver to Alliance the Know-How and any rights to Alliance's
trademarks;

            b) not to use the Know-How as long as it has to be kept confidential
pursuant to Article 8 hereof;

            c) to terminate its rights under the Licensed Patents;

            d) to make all payments accrued under this Agreement prior to the
effective termination date;

            e) to transfer all regulatory filings and approvals to Alliance upon
Alliance's written request for same; and

            f) to transfer to Alliance responsibility for and control of ongoing
work of Third Parties in an expeditious and orderly manner with the costs for
such work assumed by Alliance as of the date of notice.

      10.5 Licensee Rights. In the event that this Agreement is terminated
pursuant to Section 10.3 by Licensee, Licensee shall continue to have an
irrevocable, exclusive, license under Licensed Patents and Know-How to use and
sell Licensed Product in the Territory and to make or have made Licensed Product
anywhere in the world for use or sale in the Territory, subject only to the
obligation to pay royalties pursuant to Article 3. Further, to the extent not
already provided, Alliance will provide to Licensee all its manufacturing and
test procedure information to manufacture Licensed Product and will provide all
reasonable assistance to enable Licensee to manufacture Licensed Product and
obtain any relevant regulatory approvals for the manufacture of same.

11. MISCELLANEOUS

      11.1 Interpretation. The construction, validity and performance of this
Agreement shall be governed in all respects by the laws of the State of
Illinois, without giving effect to principles of conflict of laws.

      11.2 Force Majeure. No failure or omission by the parties hereto in the
performance of any obligation of this Agreement shall be deemed a breach of this
Agreement nor create any liability if the same shall arise from any cause or
causes beyond the control of the parties, including but not limited to the
following which, for the purposes of this Agreement, shall be

                                       11
<PAGE>

regarded as beyond the control of the party in question; act of God, acts or
omissions of any government or any rules, regulations or orders of any
governmental authority or any officer, department, agency or instrument thereof;
fire, storm, flood, earthquake, accident, acts of the public enemy, war,
rebellion, insurrection, riot, invasion, strikes, or lockouts.

      11.3 Arbitration. Any dispute arising out of or relating to this Agreement
or its breach, termination or validity which has not been resolved within ninety
(90) days of the date of delivery of the notice specified in Section 11.4 below
shall be settled in accordance with the dispute resolution provisions of the
Operating Agreement.

      11.4 Notices. Any notice required or permitted to be given under this
Agreement shall be mailed by registered or certified air mail, postage prepaid,
addressed to the party to be notified at its address stated below, or at such
other address as may hereafter be furnished in writing to the notifying party or
by telefax to the numbers set forth below or to such changed telefax numbers as
may thereafter be furnished.

            If to Alliance:

                   Alliance Pharmaceutical Corp.
                   6175 Lusk Boulevard
                   San Diego, CA  92121
                   Attention: Theodore D. Roth
                              President and Chief Operating Officer
                              Lloyd A. Rowland
                              Vice President and General Counsel
                   Facsimile: (858) 410-5306

            with a copy to:

                   Stroock & Stroock & Lavan LLP
                   180 Maiden Lane
                   New York, NY  10038
                   Attention: Melvin Epstein, Esq.
                   Facsimile: (858) 410-5306

            If to Licensee:

                   Baxter Healthcare Corporation
                   Route 120 & Wilson Road
                   Round Lake, IL  60073
                   Attention: General Manager, Global Anesthesia
                   Facsimile: (847) 270-2016

            with a copy to:

                   Baxter Healthcare Corporation
                   One Baxter Parkway

                                       12
<PAGE>

                   Deerfield, IL  60015
                   Attention: General Counsel
                   Facsimile: (847) 948-2450

            with a copy to:

                   Gibson, Dunn & Crutcher LLP
                   Jamboree Center
                   Four Park Plaza
                   Irvine, CA  92614-8557
                   Attention: Thomas D. Magill, Esq.
                   Facsimile: (949) 475-4648

      Any such notice shall be deemed to have been received when it has been
delivered in the ordinary course of post or received by telefax.

      11.5 Waiver. The failure on the part of Alliance or Licensee to exercise
or enforce any rights conferred upon it hereunder shall not be deemed to be a
waiver of any such rights nor operate to bar the exercise or enforcement thereof
at any time or times thereafter.

      11.6 Legality. In the event that any term of this Agreement shall
contravene the laws and/or regulations in any country of the Territory, the
parties shall immediately meet in order to agree on any necessary amendments,
provided that any clauses thereby rendered unenforceable shall in no way affect
the validity of this Agreement.

      11.7 Entire Agreement. This Agreement constitutes the entire agreement
between the parties hereto concerning the subject matter hereof and any
representation, promise or condition in connection therewith, not incorporated
herein, shall not be binding upon either party.

      11.8 Assignment. Except as expressly authorized, this Agreement, and all
rights and obligations hereunder, are personal as between the parties and shall
not be assigned in whole or in part by any of the parties to any other person or
company without the prior written consent of the other party.

      11.9 Titles. It is agreed that the marginal headings appearing at the
beginning of the numbered Articles hereof have been inserted for convenience
only and do not constitute any part of this Agreement.

      11.10 Publicity. Neither party shall originate any publicity, news release
or public announcements, written or oral, whether to the public or press,
stockholders or otherwise, relating to this Agreement, including its existence,
the subject matter to which it relates, performance under it or any of its
terms, to any amendment hereto or performances hereunder without the prior
written consent of the other party, provided however, that this Section 11.10
shall not be applicable where either party hereto is legally required to make
public, a summary or details of this Agreement, in any country. If a party
believes that it has a legal requirement to make public the existence of or any
details of or any events related in any way to this Agreement, it shall provide
a copy of any such announcement to the other party for review and approval at

                                       13
<PAGE>

least five (5) days prior to making said announcement.

      11.11 Unenforceable Provisions. Any provision hereof which is prohibited
or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective only to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof or affecting the validity or
enforceability of such provisions in any other jurisdiction.

      11.12 Others. As used in this Agreement, singular includes the plural and
plural includes the singular, wherever so required by fact or context.

      11.13 Execution. This Agreement shall be executed in two (2) counterparts
each of which shall for all purposes be deemed an original.

            [THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK]

                                       14
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their respective duly authorized officers or representatives as
of the day and year first above written.

                                       ALLIANCE PHARMACEUTICAL CORP.

                                       By:______________________________________

                                       Name:____________________________________

                                       Title:___________________________________

                                       PFC THERAPEUTICS, INC.

                                       By:______________________________________

                                       Name:____________________________________

                                       Title:___________________________________

                                       15
<PAGE>

                                                                      Schedule A
                                                            to License Agreement

Initial Territory.

      The geographic boundaries of the following countries existing as of the
date hereof and as they may be from time to time altered or modified, whether by
treaty, conquest, purchase, or otherwise, and all of the political territorial
subdivisions within such countries (including any independent nation, republic
or other territory which was formerly within any such country): United States
(including Puerto Rico), Canada, United Kingdom, France, Germany, Italy, Spain,
Austria, Belgium, Bulgaria, Greece, Ireland, Liechtenstein, Luxembourg,
Netherlands, Portugal, Switzerland, Turkey, Denmark, Finland, Iceland, Norway,
Sweden, Andorra, Gibraltar, Monaco, San Marino, Vatican City, Poland, Hungary,
Czech Republic and Slovak Republic, Slovenia, Romania, Bosnia, Croatia, Serbia,
Albania, Cyprus and the former Union of Soviet Socialist Republics (consisting
of Armenia, Azerbaijan, Belarus, Georgia, Estonia, Kazakhstan, Kyrgystan,
Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and
Uzbekistan).

Additional Territory.

      None as of the date hereof.

<PAGE>

                                                                      SCHEDULE B
                                                            to License Agreement

                                     PATENTS
                                     -------
<TABLE>
<CAPTION>

            =================              =================
                 COUNTRY                       PATENT NO.
            =================              =================
            <S>                            <C>
                   U.S.                        4,865,836
            -----------------              -----------------
                Australia                         599068
            -----------------              -----------------
                 Canada                        1,279,011
            -----------------              -----------------
              South Africa                       87/0252
            -----------------              -----------------
                 Norway                           173214
            -----------------              -----------------
                 Japan                           1943385
            -----------------              -----------------
                 Europe                        0 231 070
            -----------------              -----------------
                Hong Kong                      HK1011504
            -----------------              -----------------
                   U.S.                        5,080,885
            -----------------              -----------------
                   U.S.                        5,393,513
            -----------------              -----------------
                   U.S.                        4,987,154
            -----------------              -----------------
                Australia                         608880
            -----------------              -----------------
                 Canada                        1,316,820
            -----------------              -----------------
                 Europe                        0 307 087
            -----------------              -----------------
                 Japan                           1842180
            -----------------              -----------------
              South Africa                       88/5796
            -----------------              -----------------
                 Ireland                           64245
            -----------------              -----------------
                 Norway                           179162
            -----------------              -----------------
                   U.S.                        5,284,645
            -----------------              -----------------
                Australia                         648757
            -----------------              -----------------
                   U.S.                        5,847,009
            -----------------              -----------------
                   U.S.                        4,927,623
            -----------------              -----------------
                   U.S.                        5,077,036
            -----------------              -----------------
                Australia                         647372
            -----------------              -----------------
                 Canada                        1,333,877
            -----------------              -----------------
                 Canada                        1,335,714
            -----------------              -----------------
                 Canada                        1,338,854
            -----------------              -----------------
                 Europe                        0 480 925
            -----------------              -----------------
                 Japan                         3,002,486

</TABLE>

<PAGE>

<TABLE>
<CAPTION>

            =================              =================
                 COUNTRY                       PATENT NO.
            =================              =================
            <S>                            <C>
                   U.S.                        5,628,930
            -----------------              -----------------
                   U.S.                        5,914,352
            -----------------              -----------------
                Australia                         678418
            -----------------              -----------------
                  Europe                       0 666 736
            -----------------              -----------------
                   U.S.                        5,344,393
            -----------------              -----------------
                   U.S.                        5,451,205
            -----------------              -----------------
                  Europe                       0 627 913
            -----------------              -----------------
                   U.S.                        5,635,538
            -----------------              -----------------
                Australia                         679052
            -----------------              -----------------
                Australia                         710142
            -----------------              -----------------
                 Europe                        0 689 422
            -----------------              -----------------
                   U.S.                        5,865,784
            -----------------              -----------------
                   U.S.                        6,007,774
            -----------------              -----------------
                   U.S.                        5,726,209
            -----------------              -----------------
                   U.S.                        4,742,050
            -----------------              -----------------
                   U.S.                        4,889,525
            -----------------              -----------------
                   U.S.                        4,769,241
            -----------------              -----------------
                   U.S.                        4,919,895
            -----------------              -----------------
                 Canada                        1,288,045
            -----------------              -----------------
                 Europe                        0 265 082
            -----------------              -----------------
                   U.S.                        4,815,446
            -----------------              -----------------
                 Canada                        1,281,656
            -----------------              -----------------
                 Europe                        0 201 275
            -----------------              -----------------
                  Japan                        2,681,147
            -----------------              -----------------
                   U.S.                        5,061,484
            -----------------              -----------------
                   U.S.                        5,374,243
            -----------------              -----------------
                   U.S.                        5,073,383
            -----------------              -----------------
                   U.S.                        4,402,984
            -----------------              -----------------
                   U.S.                        4,461,717
            -----------------              -----------------
                   U.S.                        4,975,468
            -----------------              -----------------
                 Europe                        0 391 637
            -----------------              -----------------
                   U.S.                        4,993,415
            -----------------              -----------------
                Australia                         635899
            -----------------              -----------------

</TABLE>

<PAGE>

<TABLE>
<CAPTION>

            =================              =================
                 COUNTRY                       PATENT NO.
            =================              =================
            <S>                            <C>
                 Europe                        0 429 539
            -----------------              -----------------
                 Canada                        1,338,617
            -----------------              -----------------
                 France                        2,602,774
            -----------------              -----------------
                   U.S.                        4,985,550
            -----------------              -----------------
                Australia                         608761
            -----------------              -----------------
                 Europe                        0 255 443
            -----------------              -----------------
               New Zealand                        221232
            -----------------              -----------------
                Portugal                          85 425
            -----------------              -----------------
                 Canada                        1,315,778
            -----------------              -----------------
                 Ireland                           61102
            -----------------              -----------------
                  Japan                        2,110,228
            -----------------              -----------------
                  Norway                          169542
            -----------------              -----------------
                   U.S.                        5,344,930
            -----------------              -----------------
                Australia                         639008
            -----------------              -----------------
                 Europe                        0 478 686
            -----------------              -----------------
                  Japan                        2,849,471
            -----------------              -----------------
                  France                       2,665,705
            -----------------              -----------------
                   U.S.                        5,527,962
            -----------------              -----------------
                 Europe                        0 548 096
            -----------------              -----------------
                Australia                         647176
            -----------------              -----------------
                   U.S.                        5,703,126
            -----------------              -----------------
                   U.S.                        5,847,206
            -----------------              -----------------
                  France                       2,677,360
            -----------------              -----------------
                   U.S.                        5,846,516
            -----------------              -----------------
                   U.S.                        5,679,459
            -----------------              -----------------

</TABLE>

<PAGE>

                                                                      Schedule C
                                                            to License Agreement

                                  Applications

                ================================================
                        Country             Application No.
                ================================================
                           *
                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------

                -----------------------------------------------
<PAGE>

                                                                      Schedule D
                                                            to License Agreement

                                  United States

                                     Canada

                                     Austria

                                     Belgium

                                   Switzerland

                                  Liechtenstein

                                     Germany

                                     Denmark

                                      Spain

                                     France

                                 United Kingdom

                                     Greece

                                     Ireland

                                      Italy

                                   Luxembourg

                                   Netherlands

                                    Portugal

                                     Sweden

                                     Finland<PAGE>

                                                               Exhibit 10(qq)

                      MARKETING AND DISTRIBUTION AGREEMENT

      THIS MARKETING AND DISTRIBUTION AGREEMENT (this "Agreement") between
BAXTER HEALTHCARE CORPORATION, a Delaware corporation ("Baxter"), ALLIANCE
PHARMACEUTICAL CORP., a New York corporation ("Alliance"), and PFC THERAPEUTICS,
LLC, a Delaware limited liability company ("PFC"), is effective as of May 19,
2000 ("Effective Date").

                                    RECITALS

      WHEREAS, PFC has an exclusive license to technical know-how, patent
applications and patents relating to the manufacture, composition and use of
certain products capable of transporting oxygen in therapeutic effective amounts
in the bloodstream for all medical uses, including perflubron-based emulsion;

      WHEREAS, Baxter and its Affiliates have substantial knowledge and
expertise in the marketing and distribution of healthcare products; and

      WHEREAS, Baxter and PFC are interested in the distribution and
commercialization of the Product, as hereinafter defined.

      NOW, THEREFORE, the parties hereto agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

      Affiliate shall mean any entity controlling, controlled by, or under
common control with a person or other entity. For purposes of this definition,
the terms "controlling," "controlled by" or "under common control with" shall
mean the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a person or entity or through the
ownership of at least 40% of the voting securities of a person or entity.

      Alliance means Alliance Pharmaceutical Corp. and its Affiliates.

      Alliance Manufacturing and Supplier Agreement shall mean the Alliance
Manufacturing and Supplier Agreement dated as of May 19, 2000, between Alliance
and PFC, pursuant to which Alliance may manufacture and sell to PFC the Product.

      Baxter means Baxter Healthcare Corporation and its Affiliates.

      Baxter Distribution Agreements means exclusive or preferred distribution
agreements between Baxter and third parties in the Territory.

      Baxter Manufacturing and Supplier Agreement shall mean the Baxter
Manufacturing and Supplier Agreement dated as of May 19, 2000, between Baxter
and PFC, pursuant to which Baxter may manufacture and sell to PFC the Product.

* indicates confidential information which has been omitted and filed separately
with The Securities and Exchange Commission.

<PAGE>

      Competitive Product means a pharmaceutical product which has obtained
Regulatory Approval similar to the Product for temporary augmentation of oxygen
delivery in surgical patients and reducing/avoiding allogeneic blood
transfusions.

      First Commercial Sale shall mean the first sale to a third party of the
Product anywhere in the world under the approval of appropriate governmental
agencies (if any) for distribution and sale of such Product.

      JDC means the Joint Development Committee created pursuant to the
Operating Agreement.

      Management Board means the Management Board created pursuant to the
Operating Agreement.

      Medical Liaison Representatives means individuals retained by Baxter in
accordance with Section 2.7 hereunder.

      Operating Agreement means the Limited Liability Company Operating
Agreement of PFC Therapeutics, LLC dated May 17, 2000 between Alliance and
Baxter.

      Product means all injectable perfluorchemical emulsions capable of
transporting oxygen in therapeutic effective amounts in the bloodstream for all
medical uses, including therapeutic and diagnostic, which have been evaluated,
developed and/or acquired prior to this Agreement or will be evaluated,
developed and/or acquired during this Agreement, to the extent owned by,
licensed to or controlled by PFC or Alliance.

      Regulatory Approval means (1) in the United States, approval from the FDA
for marketing and promotion of the Product, or (2) outside of the United States,
an analogous order by a non-U.S. governmental agency which requires regulatory
approval prior to marketing and promotion of the Product in such non-U.S.
country.

      Subdistributors means dealers or other third parties in the Territory
appointed by Baxter during the term of this Agreement to distribute, market and
sell the Product in the Territory.

      Territory shall have the meaning ascribed to it in Section 1.18 of the
License Agreement dated May 19, 2000, between Alliance and PFC.

                                   ARTICLE II
                     MARKETING AND DISTRIBUTION OF PRODUCTS

      2.1 Commercialization.

            Territory. PFC hereby grants to Baxter an exclusive right to
promote, market, distribute and sell the Product for any approved clinical use,
including all future approved uses, in the Territory.

                                       2
<PAGE>
      2.2   Standard.

            (a) Baxter shall promote, market, distribute and sell the Product in
the Territory, provided, however, that Baxter shall not be held to "best
efforts" as construed by judicial precedent under the Uniform Commercial Code,
but rather shall use reasonable efforts to commercialize the Product. To that
effect, Baxter shall maintain and utilize a competent and adequate staff,
organization and facilities to satisfy its obligations under this Agreement.

            (b) In any country in the Territory where Baxter has a Competitive
Product that directly competes with the Product, Baxter shall not unreasonably
prefer such Competitive Product over the Product (an "Undue Preference"). An
Undue Preference shall be determined by reference to the standards and practices
that a third party not owning or controlling such a Competitive Product would
reasonably take in a competitive market to market such Competitive Product.

            (c) In the event that PFC believes that Baxter is giving a material
Undue Preference to a Competitive Product owned or controlled by Baxter, it
shall notify Baxter in writing of the circumstances underlying such belief. The
parties thereafter shall meet and confer and attempt to settle any
disagreements. If after such meetings there remains disagreement, the parties
shall submit the matter to the dispute resolution procedures set forth in
Section 3.2 hereof.

      2.3 Training. Alliance, if requested by Baxter, shall make its personnel
reasonably available for orientation and training of Baxter's personnel with
respect to selling, handling and storing the Product. Each party shall bear its
own respective costs and expenses for orientation and training; provided,
however, that PFC will be responsible for paying all reasonable expenses
incurred by an Alliance employee who is relocated to another location for an
extended period of time in conjunction with such orientation and training.

      2.4 Books and Records. Baxter shall make available to PFC all records and
information prepared by Baxter relating solely to the Product or products sold
as a unit or package with the Product, which are reasonably required to
determine compliance with the terms of this Agreement, including, but not
limited to, full and accurate books of account showing the amounts of the
Product sold hereunder and the prices paid therefor. PFC has the right to
inspect the facilities of Baxter or a Subdistributor and to audit the books and
records described in this Section 2.4.

      2.5   Affiliate and Third Party Distributors.

            (a) Baxter shall be entitled to designate Subdistributors in the
Territory during the term of this Agreement to distribute, market and sell the
Product in the Territory, provided that each such Subdistributor is either (i)
an Affiliate of Baxter, (ii) party to a Baxter Distribution Agreement, or (iii)
approved by PFC in writing prior to being engaged by Baxter, which approval
shall not unreasonably be conditioned, delayed or denied.

            (b) Baxter shall require each non-Affiliate Subdistributor to agree
in writing to be bound, and represents and warrants that each of its Affiliates
performing distribution functions under this Agreement will be bound, by and
subject to the duties and obligations of Baxter under this Agreement insofar as
such duties and obligations relate to the activities of

                                       3
<PAGE>

Subdistributor in the Territory, and agrees that the rights of Subdistributor
shall terminate and be of no force and effect upon termination of this
Agreement. Baxter shall be fully responsible for and liable to PFC with respect
to the activities of any Subdistributor with respect to the Products and the
Agreement.

            (c) Baxter shall expressly include in its agreements with
non-Affiliate Subdistributors provisions which prohibit such Subdistributor from
(i) actively distributing, marketing, selling, exporting or supplying the
Product outside of the Territory, (ii) advertising or conducting any promotional
or marketing activities with respect to the Product outside of the Territory,
and (iii) manufacturing the Product for distribution outside of the Territory.

      2.6 Meetings Concerning Marketing. The JDC shall discuss marketing
strategies in order to optimize customer acceptance and effective promotion of
the Product. All final plans, strategies and decisions regarding Product
marketing, distribution and pricing shall be made by Baxter; however, Baxter
shall take into consideration the JDC's recommendations to improve market
development.

      2.7 Medical Liaison Representatives. Until the third anniversary of the
Initial Payment Date as defined in Section 2.8 below, Baxter shall provide a
reasonable number of Medical Liaison Representatives whose primary
responsibility to Baxter shall be market development and promotion of the
Product in the United States. Such Medical Liaison Representatives shall be
considered representatives of Baxter, and shall not be employees of PFC or
Alliance. Baxter shall be responsible for paying any employment-related taxes
and expenses associated with such Medical Liaison Representatives. Medical
Liaison Representatives may engage in activities designed to support the market
development of the Product, such as advising and assisting in the development
and implementation of programs for medical school faculty, hospital residents,
transfusion committees, anesthesia departments and professional medical
societies. Baxter shall consider retaining Medical Liaison Representatives for
other countries within the Territory if appropriate.

      2.8 Baxter Market Development Fee. PFC shall make a payment to Baxter of
(i) * within thirty (30) days following the First Commercial Sale of the Product
in the Territory (the "Initial Payment Date"), (ii) * on the first anniversary
of the Initial Payment Date and (iii) * on the second anniversary of the Initial
Payment Date. If PFC does not have funds available to make such payment, any
short-fall shall be accrued and paid as soon as the Company has sufficient
funds. The payments provided for in this Section 2.8 constitute a market
development fee and do not in any way constitute a minimum market development
spending obligation by Baxter.

      2.9 Remedies for Baxter's Failure to Perform. In the event that Baxter or
a Subdistributor fails to purchase and sell or otherwise distribute the Product
in accordance with its obligations under this Article II, PFC's sole and
exclusive recourse shall be the remedies set forth in Section 3.2 below.

                                   ARTICLE III
                              TERM AND TERMINATION

      3.1 Term. This Agreement shall take effect as of the date first written
above and shall continue in force until termination of the Operating Agreement.

                                       4
<PAGE>

      3.2 Rights In Event of Failure to Perform Under Article II.

            If Baxter fails to perform its material obligations under Article
II, PFC shall have the following rights:

            (a) First, PFC must provide written notice to Baxter setting forth
the reasons why it believes Baxter has failed to perform, and Baxter shall have
sixty (60) days from the date of such notice to rectify the failure.

            (b) Second, if such failure is not corrected or if Baxter disagrees
that a failure has occurred, PFC and Baxter shall submit the dispute to the
resolution mechanism provided by the Operating Agreement.

            (c) Third, if it is determined through the dispute resolution
mechanism that Baxter failed to perform its material obligations under Article
II of this Agreement, the exclusive license granted to Baxter hereunder shall
become nonexclusive and Alliance shall be entitled to market, distribute and
sell the Product in the Territory directly or through distributors other than
Baxter. The remedies afforded in this Section 3.2 are the sole remedies for
Baxter's failure to perform its distribution obligations.

                                   ARTICLE IV
                                   TRADEMARKS

      4.1 Rights Regarding Product Trademark. Baxter shall have the exclusive
right, but no obligation, to use the name and mark (or successor name and mark)
selected by Baxter in a prominent manner on packaging, literature and
promotional material and advertising for the Product. Baxter is under no
obligation to obtain the approval of PFC prior to selecting or using the name
and mark. If Baxter's rights hereunder become nonexclusive pursuant to Section
3.2(c) above, Baxter shall grant to Alliance a nonexclusive license to use the
name and mark for the Product on reasonable and customary terms.

      4.2 Baxter's Rights. PFC and Alliance hereby acknowledge that they do not
have, and shall not acquire by virtue of this Agreement, any rights to or under
any goodwill, trademark, tradename, copyright, patent or other intellectual
property of Baxter, nor in any of Baxter's trademarks or tradenames appearing on
the label or packaging materials of the Product. PFC agrees to do nothing by act
or omission which would impair Baxter's or its Affiliates' rights, ownership and
title in the aforementioned.

                                       5
<PAGE>

                                    ARTICLE V
                                 CONFIDENTIALITY

      5.1 Nondisclosure. Baxter and PFC realize that some information received
by one party from the other pursuant to this Agreement will be confidential. It
is therefore agreed that any information received by one party from the other
which is in writing, or reduced to writing within thirty (30) days of the date
of disclosure, and designated as "Confidential," shall not during or for a
period of five (5) years after the term of this Agreement be (i) disclosed by
the receiving party to any third party, except to the extent that (A) such third
party is an employee, agent, representative or consultant for or to Baxter,
Alliance, PFC or their Affiliates or is contemplating investing in PFC or
Alliance, (B) such third party has agreed in writing to abide to these
confidentiality obligations and (C) such third party has a need to know such
information in order for the parties to perform their obligations under this
Agreement, or (ii) used by the receiving party for purposes other than those
contemplated by this Agreement.

      5.2 Permitted Disclosure. Nothing in this Agreement shall prevent the
receiving party from disclosing any such information: (i) which is or becomes
publicly known through no fault of the receiving party; (ii) which the receiving
party rightfully had in its possession prior to the disclosure to the receiving
party, or is independently developed by the receiving party, in either case as
evidenced by written documentation; (iii) which the receiving party lawfully
obtained without restriction from a third party with no secrecy or
confidentiality obligation to the disclosing party; (iv) which is approved in
writing by the disclosing party for disclosure by the receiving party; or (v)
which is disclosed pursuant to court order or as otherwise compelled by law.

                                   ARTICLE VI
                                DELIVERY/PAYMENT

      6.1 Delivery. PFC shall deliver the Product FCA the destinations specified
in orders placed by Baxter or its Affiliates. Unless otherwise agreed to in
writing, Baxter shall pay all normal freight charges and any customs duties,
foreign, provincial, state or other sales tax, federal goods and services tax or
any other sales, use, inventory, delivery, value added or like taxes of any
federal, provincial, state or local government, however imposed.

      6.2 Payment. Any purchases of the Product by Baxter from PFC shall be at
the prices set forth in Exhibit CC to this Agreement. The prices set forth in
Exhibit CC may be increased or decreased from time to time by mutual written
agreement of the parties; provided that any such transfer or unit price
adjustment shall reference this Agreement. Except to the extent otherwise agreed
to by the parties, payment of invoiced amounts shall be due within ninety (90)
days of the date PFC's invoice is received by Baxter. Payment shall be made by
check or wire transfer to an account designated by PFC. All payments due
hereunder but not paid by Baxter on the due date thereof shall bear interest at
the monthly rate which is the lesser of: (i) one and one half percent (1-1/2%)
of the amount due; and (ii) the maximum lawful interest rate permitted under
applicable law. Such interest shall accrue at such rate on a monthly basis on
the balance

                                       6
<PAGE>

of unpaid amounts outstanding from the date on which portions of such amounts
become due and owing until payment thereof in full.

                                   ARTICLE VII
                                  MISCELLANEOUS

      7.1 Assignability. Except as specifically provided by this Agreement, this
Agreement, or any of the rights or obligations created herein, may not be
assigned, in whole or in part, by either party without the written consent of
the other party; provided, however, that Baxter may freely assign its rights and
obligations hereunder to its Affiliates and successors in interest.

      7.2 Force Majeure. If either party fails to fulfill its obligations
hereunder (other than payment obligations) when such failure is due to a cause
beyond its control, including an act of nature, or other action such as fire,
flood, civil commotion, riot, war (declared and undeclared), revolution, action
by government including delays in obtaining government approvals, embargoes,
then said failure shall be excused for the duration of said event.

      7.3 Notice. Any notice or communication required or permitted to be given
by either party hereunder shall be in writing, and shall be telefaxed, delivered
by messenger or air courier, or mailed by registered or certified mail, and
addressed to the party to whom notice is given as follows:

          If to PFC:       Baxter Healthcare Corporation
                           Route 120 & Wilson Road
                           Round Lake, IL  60073
                           Attention: General Manager, Global Anesthesia
                           Facsimile: (847) 270-2016

          If to Alliance:  Alliance Pharmaceutical Corp.
                           6175 Lusk Boulevard
                           San Diego, CA  92121
                           Attention: Theodore D. Roth
                                      President and Chief Operating Officer
                                      Lloyd A. Rowland
                                      Vice President and General Counsel
                                      Facsimile: (858) 410-5306

           with a copy to: Stroock & Stroock & Lavan LLP
                           180 Maiden Lane
                           New York, NY  10038
                           Attention: Melvin Epstein, Esq.
                           Facsimile: (212) 806-6006

                                       7
<PAGE>

          If to Baxter:    Baxter Healthcare Corporation
                           Route 120 & Wilson Road
                           Round Lake, IL  60073
                           Attention: General Manager, Global Anesthesia
                           Facsimile: (847) 270-2016

          with a copy to:  Baxter Healthcare Corporation
                           One Baxter Parkway
                           Deerfield, IL  60015
                           Attention: General Counsel
                           Facsimile: (847) 948-2450

          with a copy to:  Gibson, Dunn & Crutcher LLP
                           4 Park Plaza, Suite 1700
                           Irvine, CA  92614-8557
                           Attention: Thomas D. Magill, Esq.
                           Facsimile: (949) 451-4220

      7.4 Governing Law. This Agreement shall be interpreted in accordance with
the laws of the State of Illinois, excluding its conflicts of laws principles.

      7.5 Complete Agreement. As of the Effective Date, this Agreement and the
other agreements mentioned herein represent the entire agreement between the
parties hereto with respect to the subject matter hereof. There are no
understandings, representations or warranties of any kind except as expressly
set forth herein.

      7.6 Severability. If any of the provisions of this Agreement are held void
or unenforceable, the remaining provisions shall nevertheless be effective, the
intent being to effectuate this Agreement to the fullest extent possible.

      7.7 Modification. Any modification of this agreement shall be in writing
and shall be signed by both Baxter and PFC. Any attempt to modify this Agreement
orally or in writing not executed by all parties hereto shall be void.

      7.8 Survival. Notwithstanding anything else in this Agreement to the
contrary, the parties agree that Article V shall survive the termination or
expiration of this Agreement, as the case may be.

      7.9 Headings. Any headings contained herein are for directory purposes
only, do not constitute a part of this Agreement, and shall not be employed in
interpreting this Agreement.

      7.10 Waiver. A waiver of any breach of any provision of this Agreement
shall not be construed as a continuing waiver of other breaches of the same or
other provisions of this Agreement.

      7.11 Relationship of the Parties. The parties hereto are independent
contractors. Nothing herein contained shall be deemed to create a joint venture,
agency or partnership relationship between the parties hereto. Neither party
shall have any power to enter into any

                                       8
<PAGE>

contracts or commitments in the name of, or on behalf of, the other party, or to
bind the other party in any respect whatsoever.

                             [Signatures to follow.]

                                       9
<PAGE>

      IN WITNESS THEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives as of the day and year first above
written.

                                    PFC Therapeutics, LLC

                                    By:_____________________________
                                    Name:___________________________
                                    Title:__________________________

                                    Alliance Pharmaceutical Corp.

                                    By:_____________________________
                                    Name:___________________________
                                    Title:__________________________

                                    Baxter Healthcare Corporation

                                    By:_____________________________
                                    Name:___________________________
                                    Title:__________________________

                                       10
<PAGE>

                                   Exhibit CC

      Baxter shall purchase the Product from PFC *.

            "ASP" means the average selling price of the Product in the
Territory expressed in U.S. dollars calculated by dividing the Net Sales to
Trade Customer for all countries in the Territory by the total Units sold in the
Territory during the relevant Fiscal Year.

            Capitalized terms used herein but not otherwise defined in this
Agreement or Exhibit CC shall have the meanings ascribed to them in the
Operating Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]